Intranasal vardenafil claims faster absorption but lacks clinical validation

LTR Pharma is promoting Roxus, a compounded intranasal vardenafil formulation, based on small healthy-volunteer pharmacokinetic studies and limited retrospective self-reported outcomes. The formulation is not FDA-approved for safety or efficacy, and faster absorption has not established better erections or long-term safety.